MX2010010876A - Piperidinas sustituidas como compuestos terapeuticos. - Google Patents

Piperidinas sustituidas como compuestos terapeuticos.

Info

Publication number
MX2010010876A
MX2010010876A MX2010010876A MX2010010876A MX2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A
Authority
MX
Mexico
Prior art keywords
therapeutic compounds
substituted piperidines
compounds
piperidines
substituted
Prior art date
Application number
MX2010010876A
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Stefan Stutz
Aleksandar Stojanovic
Dirk Behnke
Vincenzo Tschinke
Stjepan Lakovic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010010876A publication Critical patent/MX2010010876A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de la fórmula general (1): (ver fórmula (I)) y la sal farmacéuticamente aceptable de los mismos, en donde R1 tiene las definiciones ilustradas con detalle en la descripción, como inhibidores de beta-secretasa, catepsina D, plasmepsina II, y/o proteasa de VIH.
MX2010010876A 2008-04-02 2009-04-01 Piperidinas sustituidas como compuestos terapeuticos. MX2010010876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08153929 2008-04-02
PCT/EP2009/053898 WO2009121914A1 (en) 2008-04-02 2009-04-01 Substituted piperidines as therapeutic compounds

Publications (1)

Publication Number Publication Date
MX2010010876A true MX2010010876A (es) 2010-10-26

Family

ID=40627638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010876A MX2010010876A (es) 2008-04-02 2009-04-01 Piperidinas sustituidas como compuestos terapeuticos.

Country Status (10)

Country Link
EP (1) EP2271644A1 (es)
JP (1) JP2011516453A (es)
KR (1) KR20110002459A (es)
CN (1) CN101970431A (es)
AU (1) AU2009232012A1 (es)
BR (1) BRPI0910991A2 (es)
CA (1) CA2719070A1 (es)
EA (1) EA201001517A1 (es)
MX (1) MX2010010876A (es)
WO (1) WO2009121914A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057160A2 (en) * 2009-11-06 2011-05-12 The Regents Of The Uiversity Of California Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
GB201008209D0 (en) * 2010-05-17 2010-06-30 Senexis Ltd Compounds
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
CN105001300A (zh) * 2014-04-17 2015-10-28 复旦大学 组织蛋白酶d抑制剂及其制备方法、药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds

Also Published As

Publication number Publication date
WO2009121914A1 (en) 2009-10-08
CN101970431A (zh) 2011-02-09
AU2009232012A1 (en) 2009-10-08
CA2719070A1 (en) 2009-10-08
KR20110002459A (ko) 2011-01-07
JP2011516453A (ja) 2011-05-26
EA201001517A1 (ru) 2011-04-29
EP2271644A1 (en) 2011-01-12
BRPI0910991A2 (pt) 2016-01-19

Similar Documents

Publication Publication Date Title
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201070786A1 (ru) Бензофуропиримидиноны
MY153915A (en) Organic compounds
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
NO20091395L (no) Nye tiofenderivater
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA201170521A1 (ru) Новые соединения
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
TNSN08191A1 (en) Kinase inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MY153921A (en) Aminopyrazole derivatives
TW200833324A (en) Sulfonamide derivatives
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
EA201270590A1 (ru) Ингибиторы акт
MX2010009927A (es) Derivados de espiroindolinona.
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
NO20081292L (no) Pentasykliske kinaseinhibitorer
TW200744612A (en) New combination

Legal Events

Date Code Title Description
FA Abandonment or withdrawal